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Executive Summary

Beginning in the 1990s, a new kind of philanthropy emerged that was formulated on the
premise of merging philanthropy with investing. The concept of turning philanthropy into social
investing was coined venture philanthropy and has received substantial attention since its
inception.

Generally speaking, if the business model of the organization shows promise,

investors will narrow their focus to that organization for multiple years rather than committing to
one-year grants (Community Health Ventures for the Morino Institute 2010). In view of this,
investors will engage in long term relationships and partner with the organization to support
capital needs.
The Cystic Fibrosis Foundation, Juvenile Diabetes Research Foundation, and Michael J.
Fox Foundation for Parkinson’s Research are three disease-focused foundations that practice
venture philanthropy in order to proactively identify and fill key gaps in public funding. Each
nonprofit has a different focus, but each has a mission that is focused on providing efficient,
effective, and transparent services, such as drug development, to a patient population that
requires assistance. Each of these nonprofits was founded by individuals affected by the disease
they support and has experienced both success and challenges during its lifespan. Conducting an
analysis of these foundations gives a concentrated snapshot of the benefits and shortcomings of
venture philanthropy as a nonprofit business model.
i
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Venture Philanthropy:
A Case Study of Three Nonprofit Organizations

Introduction
Beginning in the 1990s, a new kind of philanthropy emerged that was formulated on the
premise of merging philanthropy with investing. This new development was, in part, a result of
the 1991 democratic campaign that called on Americans to make greater and more consistent
contributions, or social investments, that would lead to greater social impact. The concept of
turning philanthropy into social investing was coined venture philanthropy and has received
substantial attention since its inception.

Generally speaking, if the business model of the

organization shows promise, investors will narrow their focus to that organization for multiple
years rather than committing to one-year grants (Community Health Ventures for the Morino
Institute 2010). Investors engage in long term relationships and partner with the organization to
support capital needs. In the following analysis, an exploratory case study of three nonprofit
organizations that follow the venture philanthropy model is deployed to investigate the
organization’s best practices to determine whether or not the organization’s missions are being
realized. The organizations explored are: Cystic Fibrosis Foundation (CFF), Juvenile Diabetes
Research Foundation (JDRF), and Michael J. Fox Foundation for Parkinson’s Research (MJFF).
The results of this case study are straightforward: for this very small focus group of nonprofit
organizations, venture philanthropy has proven to be an effective model by which to operate.
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Literature Review
Venture philanthropists, according to Peter Frumkin, transfer wisdom across sectors.
Their approach and language has penetrated the private and community foundation world, the
small giving circles and clubs that help guide new donors, and the territory of corporate
philanthropy.

To date, venture philanthropy has been tried in environments such as early

childhood health, environmental protection, public health, and education. Although venture
philanthropy is still relatively small in comparison to the billions of dollars donated per year
across the country, its influence is growing with increased media attention, and more
significantly, with the recent development of some of the nation’s largest nonprofit organizations
adopting its language and practices.
As Frumkin (2003) describes, venture philanthropy can be viewed as a three-legged stool,
each representing a solution to a problem in traditional philanthropy practice. These three legs
are: capitalization, engagement, and performance measurement. Frumkin suggests that scholars
consider each of these “legs” separately to see how they support effective giving. In terms of
engagement, venture philanthropy has focused on changing the relationship between the funder
and recipient. Many disease foundations, for example, subscribe to venture philanthropy due to
frustration with the slow pace of the traditional medical system (Chang 2010).

Venture

philanthropists believe the “work” begins once a financial commitment has been made. Often,
venture philanthropies are collaborative, results-oriented, and mission-driven. Cultivating longterm relationships with investors can provide nonprofits with useful connections which could
ultimately result in diversifying funds by connecting high net-worth investors in the
organization’s donor pool with a venture capitalist on the organization’s Board of Directors
(Community Health Ventures for the Morino Institute 2011). Another advantage of an engaged
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relationship is investor satisfaction. Cultivating and engaging relationships with investors has
very little to do with nonprofit performance. The experience that an investor has with the
nonprofit is most important because, in venture philanthropy, the investor is a long-term
supporter who is kept up to date with programs and financials needs of the organization. As
Rececca Wyhot (2004) states, “the nature of the nonprofit venture philanthropy relationship is
involved, passionate, supportive, financially invested, proactive, accessible, and more committed
than other funders.”

Nonprofit organizations that follow the venture philanthropy model,

particularly healthcare organizations, have been founded by patients and families to provide a
service for a population that has been left without support or service by the government.
According to Frumkin (2003), venture philanthropists distinguish their work by the way
they assess results.

Venture philanthropists are particularly concerned with performance

measurement and have made it the focal point of their approach to giving. The calculation of
social return on investment is very much an application of a cost-benefit analysis that has been a
key tool in the private sector for decades. The ability to calculate social return on investment has
given venture philanthropy a language that appeals to younger investors. Similarly to the first
leg of venture philanthropy, performance measurement is not without challenge. The challenge
venture philanthropy faces is the reality of performance measurement in the nonprofit setting. It
is very difficult to measure the benefits of philanthropic practice particularly when, in many
cases, it has little relevance when applied to measurement. For example, the income streams of
nonprofits can be estimated, but parts of nonprofit programs, for example, advocacy efforts,
counseling, and arts performances, are difficult to monetarily quantify. The challenge facing
venture philanthropy as the concept matures will be translating “making a difference” into
monetary terms for those investors who demand a tangible return on social investment.

3

Venture philanthropy has developed a different approach to funding, one that builds on
venture capital and offers longer term support and larger amounts of unrestricted financial
support. This model emphasizes long-term funding designed to help organizations develop and
grow.

In her thesis, Joanne Chang (2010) investigates disease focused foundations (DFFs) in

relation to venture philanthropy. Many DFFs, including the three nonprofits explored in this
paper, serve a niche population which often experiences difficulty making medical advancements
in today’s medical environment. Such DFFs seek to create functioning markets where they
perceive market-failure. In the case of many DFFs, market-failure occurs in the transition from
the laboratory to clinical trials. The DFFs de-risk drug candidates in the drug discovery pipeline
chain as the majority of drug development companies, pharmaceutical companies, and medical
device companies tend not to engage and invest in the small markets that DFFs serve. DFFs
provide capital during the drug development life cycle at the point where it is usually most
scarce. DFFs proactively identify and fill gaps in public funding by funding high-risk, highreward projects with a sound scientific basis (Odling-Smee 2007).

Methodology and Limitations
The following analysis outlines the core structure of the Cystic Fibrosis Foundation
(CFF), Juvenile Diabetes Research Foundation (JDRF), and Michael J. Fox Foundation for
Parkinson’s Research (MJFF).
For each nonprofit organization, an analysis of strengths, weaknesses, opportunities, and
threats (SWOT analysis) of an organization was used to determine if venture philanthropy could
be considered a best practice to serve its respective population and mission effectively,
efficiently, and with transparency. The limitation of conducting a SWOT analysis is that it is
exploratory in nature and cannot be used as a measure to determine if venture philanthropy is an
4

appropriate model for all nonprofit organizations. For example, the organizations reviewed
within this paper are healthcare nonprofit organizations which serve niche populations in the
United States. The three SWOT analyses of these very specific organizations in one territory
could not supply enough evidence in support of or opposition to venture philanthropy as a
foundation model across all markets.

Findings
The Cystic Fibrosis Foundation, Juvenile Diabetes Research Foundation, and Michael J.
Fox Foundation for Parkinson’s Research are disease foundations that practice venture
philanthropy in order to proactively identify and fill key gaps in public funding. Each nonprofit
has a different focus, but each has a mission that is focused on providing efficient, effective, and
transparent services, such as drug development, to a patient population that requires assistance.
Each of these nonprofits was founded by individuals affected by the disease they support and has
experienced both success and challenges during its lifespan. Conducting an analysis of these
foundations gives a concentrated snapshot of the benefits and shortcomings of venture
philanthropy as a nonprofit business model.

The Cystic Fibrosis Foundation
Founded in 1955, the mission of the Cystic Fibrosis Foundation (CFF) is to support the
development of new drugs to fight the disease, improve the quality of life for those with cystic
fibrosis (CF), and ultimately to find a cure (Cystic Fibrosis Foundation 2011). The Foundation
funds and accredits more than one hundred and fifteen care centers, ninety adult care centers,
fifty affiliate programs and eighty chapters and branch offices nation wide. The Cystic Fibrosis
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Foundation is one of the most efficient organizations of its kind as a recipient of a 4-Star rating
for sound fiscal management from Charity Navigator, and the accreditation by the Better
Business Bureau’s Wise Giving Alliance.
The Cystic Fibrosis Foundation asserts that until cystic fibrosis is cured, the Foundation
will serve as the following six things: scientific pioneers, fund-raisers, advocates, investors,
caregivers, and family. As scientific pioneers CFF partially funds the research and development
of drug therapies necessary for CF patients.

The Foundation has broadened its de-risking

activities by investing more capital into therapies that are in Phase II and Phase III trials (Cystic
Fibrosis Foundation 2011). The Cystic Fibrosis Foundation created a therapeutic drug pipeline
that maps CFF supported drug therapies from the laboratory research stage to the end of the
lifecycle where it is made available to patients (see Appendix A). The Foundation uses a point
system to judge the progress of the pipeline from a bottom-up approach in conjunction with a
top-down life expectancy measure. The Cystic Fibrosis Foundation takes many “shots of goal”
to diversify its portfolio and to fill the gaps left open in care and drug development (Cystic
Fibrosis Foundation 2009). Only 30,000 individuals in the United States are affected by cystic
fibrosis; therefore, it is extremely important that the Foundation acts as an advocate for those
with the disease. CFF dedicates a portion of its efforts educating the general public about the
disease and attempting to gain legislative support. Additionally, the Foundation funds care
centers, clinics, and pharmacies to help control the effects of the disease, but those control efforts
are only fully realized with the support of family.
The Foundation’s strategic plan is characterized as a plan that addresses the questions
“where we want to go” and “how we’re going to get there.” CFF’s five-year objectives represent
the “where we want to go” aspect of the strategic plan which has four phases: developing new
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medical treatments for people with cystic fibrosis; delivering high-quality, compassionate patient
and family-centered care through the Care Center Network; helping patients and their families
find new ways to improve their self-management skills; and expanding access to quality cystic
fibrosis care.
The second aspect of the Cystic Fibrosis Foundation’s strategic plan is characterized as
the “how we’re going to get there” phase. The Foundation says it will accomplish its objectives
by working toward the following four goals: continuing to explore and develop new ways to
fund the mission; continuing to nourish and maintain the “people pipeline,” continuing to
evaluate and improve the effectiveness of communications, taking full advantage of new means
and strategies for reaching various audiences; and enhancing organizational structure so that all
departments optimally align with the Foundation’s science and medical program. Each of the
four goals has specific sub-goals, which further demonstrate how the Foundation is going to
reach its objectives listed in the first phase.
In order to explore and fund its mission, the Foundation is working to continue to grow
its major fundraisers, such as its highest grossing, grassroots walk-a-thon, Great Strides, and
other special events. The Foundation is also actively working to establish Corporate Leadership
Council to help garner increased commitment from the corporate community. This particular
sub-goal is one that has been fully adopted by the chapters and affiliates.
The Cystic Fibrosis Foundation has numerous strengths. From an overall perspective,
structure is a major strength. As illustrated with its strategic plan, the concept of having a
national office that disperses information to the chapters and affiliates is an efficient method of
management.

The national office is responsible for action plans, major decisions, human

resources, and governance while the chapters are responsible for enacting those functions.
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The Cystic Fibrosis Foundation prides itself on accountability. As noted previously, the
Foundation has met the standards of the Better Business Bureau’s Charity Accountability whose
standards include how charities govern their organization, the ways it spends money, the
truthfulness of its representations, and its willingness to disclose basic information to the public.
Additionally, the Foundation has an A- rating from the American Institute of Philanthropy whose
standards include the percentage spent on charitable purpose and the cost to raise $100. One of
the Foundation’s selling points to donors is a statement based on efficiency. The Foundation
says that for every dollar it receives, ninety cents of it goes to its mission.
Progress and drug development are two major strengths of the Foundation. When an
organization represents a small population of people, it is paramount that its efforts continue to
move forward. Today, there are currently thirty drugs working through the pipeline which is
more than double what was available just ten years ago.

The tangible progress that the

Foundation can illustrate is what inspires donors with no connection to the disease to keep
working towards the mission.
Like many nonprofit organizations, the Cystic Fibrosis Foundation has weaknesses that
sometimes negatively affect the organization’s ability to support its mission. In the case of CFF,
high-risk projects in the past ten years have, in some cases, led to disappointing results that have
cost the organization investors and accountability ratings.

The Cystic Fibrosis Foundation

protects its intellectual property, meaning the research it has funded towards drug development,
and sometimes exercises its right to pursue relationships with pharmaceutical or development
companies that may offer better odds of the drug to coming to fruition. In two cases last year,
the Cystic Fibrosis Foundation had incidents with two pharmaceutical companies that had
insufficient capital to finish its projects and thus the Foundation partnered with a different
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clinical development company to increase the odds of the venture succeeding. These kinds of
business decisions sometimes lead to decreased support by investors, particularly inexperienced
investors. Unfortunately, some business maneuvers made by CFF led to its Charity Navigator
Rating to be decreased from a 4-Star to a 3-Star rating in 2011 (Charity Navigator 2011).
Similarly to the vast majority of nonprofit organizations, the Cystic Fibrosis Foundation does
experience staff and volunteer burn out which leads to decreased fundraising which directly
funds the Foundation’s research and development arms. Being an orphan disease, a disease that
affects less than 200,000 people in the United States, is both a weakness and opportunity for the
Cystic Fibrosis Foundation (Rare Diseases Act of 2002). The disease inherently serves as a
weakness for the C.F. Foundation because the pharmaceutical industry has little financial
incentive for the private sector to make and market new medications to treat or prevent the cystic
fibrosis; therefore, the burden of funding medical research and drug therapies is left solely to the
Foundation and its investors which can create a very delicate situation.
Health organizations, like the Cystic Fibrosis Foundation, have the great opportunity to
save lives. The Cystic Fibrosis Foundation in particular has the distinct opportunity to find a cure
for the disease, a concept that was validated on October 19, 2011 when the Cystic Fibrosis
Foundation’s partnership with Vertex Pharmaceuticals resulted in the application to the United
States Food and Drug Association (FDA) approval for KALEYDECO.

If approved,

KALEYDECO will be the first drug on the market that targets the underlying cause of cystic
fibrosis (Vertex Pharmaceuticals Incorporated 2011).
The greatest threat to the Cystic Fibrosis Foundation is keeping the pharmaceutical
companies, medical equipment companies, and researchers engaged in developing new therapies
and equipment for cystic fibrosis patients.

The state of the economy coupled with the
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opportunity for greater profits with other forms of medical research often leads the companies to
back out of their obligations with the CFF. In terms of drug development, the most critical piece
of the CF Foundation’s business model, typically, pharmaceutical companies abandon the project
between Stages 2 and 3, the point in which they take over funding. While the Cystic Fibrosis
Foundation has rights to the intellectual property gained in the partnership, the threat is losing
time and donor support over market failures.
Juvenile Diabetes Research Foundation
The Juvenile Diabetes Research Foundation (JDRF) is the leading organization
researching the cure for Type 1 Diabetes (T1D). It sets the global agenda for diabetes research,
and is the largest charitable funder and advocate of diabetes science worldwide. The mission of
JDRF is to find a cure for diabetes and its complications through the support of research. Type 1
Diabetes is an autoimmune disease that strikes children and adults suddenly, and can be fatal.
Until a cure is found, people with T1D have to test their blood sugar and give themselves insulin
injections multiple times or use a pump—each day, every day of their lives. Despite the intensive
care, insulin is not a cure for diabetes, nor does it prevent its potential complications, which may
include kidney failure, blindness, heart disease, stroke, and amputations (Juvenile Diabetes
Research Foundation 2010a).
Since its inception in 1970 by parents of children with T1D, JDRF has awarded more
than $1.5 billion to diabetes research, including $107 million last year (Juvenile Diabetes
Research Foundation 2009). More than 80 percent of JDRF's expenditures directly support
research and research-related education. JDRF has made a substantial impact on the landscape
of Type 1 diabetes research by funding the basic research necessary to develop drug therapies
and translate scientific findings to finding a cure. The Juvenile Diabetes Research Foundation
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plays a unique role in developing and setting the landscape for Type 1 diabetes research by
partnering with academia, pharmaceutical and biotechnology companies, venture capitalists,
government entities, and other foundations to fund a cure for Type 1 diabetes (Juvenile Diabetes
Research Foundation 2009).
The research goals of JDRF are to stop Type 1 diabetes or slow its progression in people
who are newly diagnosed, reverse Type 1 diabetes, and prevent or reverse its complications, in
those who have lived with the disease for years, to prevent Type 1 diabetes in people at risk and
in future generations, and to improve treatment of Type 1 diabetes and provide better tools to
achieve tight glucose control for people at all stages of the disease.

JDRF targets its research

funding efforts into two areas: cure and control. Funding for the cure includes immune therapies
and beta cell therapies while control research funding encompasses glucose control and
complications therapies. Last year, JDRF invested $32 million to immune therapies, $35 million
to beta cell therapies, $23 million to glucose control, $17 million to complications therapies
bringing the JDRF’s investment to the mission to $107 million dollars (Juvenile Diabetes
Research Foundation 2009).
JDRF is the leader in setting the agenda for Type 1 diabetes research worldwide, and is
the world's largest charitable funder and advocate of Type 1 diabetes research. JDRF uses its
research leadership to bring about collaborations between top researchers in diverse fields to
focus their energies on finding cures for T1D and its complications. JDRF’s influence allows the
foundation to ensure that the best researchers are searching for the cure.
Juvenile Diabetes Research Foundation excels in large part due to the exceptional
organization of the Foundation. JDRF has six strategic therapeutic objectives against which each
project is measured. With an average of $2 million invested by the Foundation per project, it is
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necessary that JDRF have some system of accountability to ensure that the mission is being
fulfilled.

One of the most impressive strengths of JDRF is the Industry Discovery and

Development Partnerships (IDDP) initiative. IDDP seeks to create partnerships with biotech and
pharmaceutical companies focusing on the discovery, development, and commercialization of
therapeutics and devices for Type 1 diabetes (Juvenile Diabetes Research Foundation Industry
and Discovery Development & Partnerships 2010b). At its inception, IDDP reached out to its
partners for support, but over time, industry leaders interested in JDRF’s mission have
approached the organization rather than JDRF initiating the first contact. The IDDP therapeutic
pipeline outlines the progress this initiative has made since 1970 mapping drug development
from the laboratory to availability to patients (see Appendix B).
The Juvenile Diabetes Research Foundation has an incredibly large network of investors
and stakeholders that fuel the mission. While this network of people is a major advantage,
having such a network serves as a challenge as nonprofits of this caliber often struggle with
inexperienced investors, micromanagement of staff, researchers, investors, and committees, and
combating the image of being a controlling foundation. For example, JDRF has an in-house
research department that works with external advisors to identify and recommend funding
opportunities. This department manages relationships on behalf of the Foundation which has the
potential to pose challenges when selecting, or not selecting, projects to fund. The Juvenile
Diabetes Research Foundation has done due diligence concerning this challenge by having an
advisory group of venture capitalists, biotech professionals, Board of Directors staff, and
Foundation staff that analyze its project selections.
The Juvenile Diabetes Research Foundation performs gap analysis sessions to categorize
problems in funding and science. These sessions identify both opportunities and threats in the
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Foundation’s future. JDRF identifies opportunities for future investments during gap analysis
sessions that have the potential to lead to new, ground breaking developments to serve its
mission. A unique opportunity JDRF has is government funding. There are 18.8 million people
in the United States diagnosed with diabetes and another estimated 7 million undiagnosed which
takes Type 1 diabetes out of the orphan disease classification (Juvenile Diabetes Research
Foundation 2010a). T1D is an epidemic in the United States, and for that reason, JDRF has the
opportunity to capitalize on the country’s support of finding a cure for a disease that affects a
large percentage of Americans. Similarly to the C.F. Foundation, JDRF is threatened by highrisk investments that have the potential to yield disappointing results to investors and patients.
As with other disease foundations, it is necessary to invest in high-risk projects to increase the
probability of new drug therapies to complete the lifecycle and make available to the patient
population.

The Michael J. Fox Foundation for Parkinson’s Research
The mission of the Michael J. Fox Foundation for Parkinson’s Research (MJFF) is to find
a cure for Parkinson’s disease (PD) through an aggressively funded research agenda and to
ensure the development of improved therapies for those living with Parkinson’s today. The
foundation has a strong network of human resources that keep the organization moving forward
such as the Board of Directors, Founder’s Council, Leadership Council, Patient Council,
Scientific Advisors, and finally, the Foundation staff.
The Michal J. Fox Foundation Board of Directors is comprised of leaders in science,
business, fundraising, and entertainment. According to the Foundation’s website, the Board’s
expertise helps forge the path for Parkinson’s research, assess the Foundation impact, and guide
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the pursuit of improved Parkinson’s treatments, and ultimately, a cure. Formed in 2008, the
Foundation’s Founders’ Council was created to recognize individuals who have made significant
and transformative contributions to the Foundation’s efforts. These individuals may have served
on the Board at the time of their contribution or may have served as advisors to the Foundation.
The members of the Founder’s Council continue to serve the Foundation on an as-needed basis
often providing advice in their areas of expertise. The Leadership Council of the MJFF serves as
an advisory Board to the Foundation that provides financial support and strategic insight on how
to effectively and efficiently move towards a cure. In 2008, MJFF created the Patient Council
that is a formal channel for the Foundation to solicit input from Parkinson’s disease (PD) patients
and the broader Parkinson's community. The Council advises the Foundation on programmatic
fronts including: strategies to best convey patient priorities to the research community and its
funders; content and emphasis for patient education and outreach relevant to MJFF's mission to
find a cure; patient roles in developing novel ways to conduct research; and mechanisms for
impact assessment.
One of the most unique aspects of MJFF’s network of human resources is the network of
Scientific Advisors. The Foundation’s Scientific Advisory Board is a group of leading
Parkinson’s researchers from both academia and industry, clinicians who work with Parkinson’s
patients, and experts from related fields. These members come from all over the world to attend
grant review assessments, workshops, and other relevant meetings to help determine which
research programs will get the Foundation closer to improving Parkinson’s treatments and curing
the disease (Michael J. Fox Foundation for Parkinson’s Research 2010).
The Michael J. Fox Foundation for Parkinson’s Research has one clear measure of
success: delivering patients better treatments and, ultimately, a cure for Parkinson's disease.
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MJFF has developed a targeted approach to research funding that helps identify and prioritize the
patient-relevant science that will allow the Foundation to reach its goal.

The following chart

exemplifies the MFJJ approach:

In the first stage of the approach, charting the course, the Foundation approaches leading
specialists from around the globe to help maintain a comprehensive view of the field and
determine the research areas that hold the most promise for improving diagnosis and treatment of
Parkinson’s disease. In 2006, MJFF convened over 350 top researchers from academic and
industry labs all over the world for meetings to set strategy and future direction (Michael J. Fox
Foundation for Parkinson’s Research 2010). These meetings lead directly to funding initiatives,
new collaborations and other action steps that will move the field forward faster. The second
stage of the MJFF approach is the selection process. In this process, the Foundation's scientific
staff and expert advisors review proposals from researchers around the world. The staff and
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scientists are searching for ideas that are most readily translatable into new treatments, the teams
that can execute those ideas, thoughtful and realistic work plans, and outcomes that can take
them closer to the MJFF goal: delivering better treatments and, ultimately, a cure for PD. In the
third stage, the research process, MJFF eliminates red tape to get funding to scientists as quickly
as possible. MJFF funds projects quickly—in most cases, within two months. Scientific staff and
advisors stay closely involved as research teams carry out their projects. MJFF establishes
milestones and evaluates outcomes and progress. One of the ways MJFF conceptualizes and
quantifies success is its Drug Development Pipeline, a common measure characteristic of health
foundations, which maps the progress of funded drug therapies through the drug lifecycle (see
Appendix C). Additionally, MJFF troubleshoots problems if they arise, and work with the team
to set future directions. MJFF’s interactive approach is its take on venture philanthropy. In
comparison to other organizations, MJFF does not have an established record of moving as many
drug therapies through the lifecycle of the pipeline, but the Foundation does use venture
philanthropy as a measure of accountability.
The Michael J. Fox Foundation for Parkinson’s Research excels in capitalizing on results.
When MJFF learns of promising findings, whether or not they resulted from research funded by
the Foundation, it works quickly to identify and partner with researchers equipped to further
develop those discoveries in pursuit of the ultimate goal (Michael J. Fox Foundation for
Parkinson’s Research 2008). MJFF is unique in the sense that it capitalizes on research funded
both by its own researchers and by others. Since its inception in 2000, the Foundation has
funded more than $264 million in Parkinson's research, either directly or through partnerships
(Michael J. Fox Foundation for Parkinson’s Research 2010).
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Like the Cystic Fibrosis Foundation and Juvenile Diabetes Research Foundation, the
Michael J. Fox Foundation for Parkinson’s Research understands that science is risky by nature.
The Foundation addresses the fact that not all research leads to positive outcomes but asserts that
even negative outcomes are useful for informing the next steps. One weakness that could be
noted of MJFF is that it does not have an endowment fund and relies entirely on fundraising and
cultivating relationships to fund science and research. Without an endowment or government
assistance, MJFF runs the high risk of losing vital financial support at the onset of disappointing
results despite their position on research outcomes.
The Michael J. Fox Foundation for Parkinson’s Research has the opportunity to continue
to make great progress in PD research and care by continuing to cultivate relationships with
industry heavy weights to fund research projects in cooperation with the Foundation. As an
added opportunity for investors, the Foundation uniquely does not require that a company make
a 1:1 match with MJFF to invest in a project which serves as a major incentive (Michael J. Fox
Foundation for Parkinson’s Research 2010).
The Michael J. Fox Foundation for Parkinson’s Research is threatened by two things: its
position on endowment funds and company matches. Having these funds in reserve provides a
safety net for the organization—in short, should MJFF be affected by the economy or a damaged
relationship with a key donor, the safety net of an endowment fund or company match would
allow for research to continue and stride toward the ultimate goal of finding a cure for PD.

Conclusions
The results of this case study are straightforward: for this very small focus group of
nonprofit organizations, venture philanthropy has proven to be an effective model by which to
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operate. Venture philanthropy is an innovative way for organizations, particularly diseasefocused organizations, to streamline funds directly into serving their missions.

Venture

philanthropy has proven to be particularly beneficial to organizations that serve an orphan
disease, or less than 200,000 individuals, in the United States.
A common challenge that the Cystic Fibrosis Foundation, Juvenile Diabetes Research
Foundation, and Michael J. Fox Foundation for Parkinson’s Research share is the difficulty to
see drug therapies through the lifecycle of development.

For pharmaceutical and medical

companies, the risk and expense of developing a drug therapy or medical device is not enough
for the companies to invest in seeing the project from development to market availability.
Venture philanthropy allows for organizations to invest in the development of drug therapies
and/or devices at the most risky points of development where projects run the most risk of
having market-failure. A recommendation for nonprofits that invest in drug development would
be to consider intellectual property when making business decisions. For example, the Cystic
Fibrosis Foundation sold the intellectual property to a promising drug coming through the
pipeline and was able to use the proceeds of that transaction to fund KALEYDECO, the drug
therapy earlier mentioned as the first oral medication for cystic fibrosis that targets the cause of
the disease. Garnering funds for such large investments as drug development requires extensive
fundraising, cultivating high net worth donors, and maximizing capital by all means possible.
Each of the three foundations analyzed uphold the four core principles of public
administration: effectiveness, efficiency, economy, and equity. In terms of effectiveness, each
organization develops standards by which success is measured—for each of the organizations, a
therapeutic drug pipeline serves as a quantifiable measure of success. Each organization can
clearly demonstrate that through the funding provided for its projects, there have been results.

18

Both the Cystic Fibrosis Foundation and Juvenile Diabetes Research Foundation have drugs
therapies that have completed the entire cycle from laboratory research to the patient market
which is a clear measure of effective philanthropy.

Venture philanthropy, as a practice, is

extremely efficient and each of the foundations analyzed discuss at length the efficiency of the
organization, particularly in reference to funding. Each organization has no less than a 3-Star
rating on Charity Navigator, a trusted source in evaluating the efficiency of nonprofit
organizations. The Cystic Fibrosis Foundation, for example, prides itself on its tagline of “ninety
cents of every dollar raised” going to fuel the mission of the organization.
In terms of accountability and transparency, the Cystic Fibrosis Foundation, Juvenile
Diabetes Research Foundation, and Michael J. Fox Foundation for Parkinson’s Research have
developed superior measures for ensuring that both principles are acknowledged and upheld.
Each foundation has a Board of Directors and various committees whose responsibilities are to
assist in governing the organization. The Juvenile Diabetes Research Foundation has several
medical and research committees for assessing projects in the therapeutic pipeline and making
decisions based on science that determine the amount of funding the project will receive.
Additionally, each organization has an internal and external audit for compliance and tax
purposes in addition to having a 501(c)3 tax exempt status with the federal government.
As venture philanthropy matures, it is probable that it will further gain the support of
sophisticated donors. It is undeniable that organizations across the United States, beyond the
three organizations analyzed in the preceding analysis, have accomplished ambitious milestones
with the direction of this model. The Michel J. Fox Foundation for Parkinson’s Research is an
excellent example of young and successful venture philanthropy. Since its inception in 2000, the
Foundation has initiated six programs that serve six different goals for the Foundation’s
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mission—from evaluating targets to initiating a drug discovery program, the Foundation
provides the capital to aggressively fill the gaps in public funding and support. Ultimately, the
most important principle of nonprofit organizations is public service. Venture philanthropies are
designed to serve percentages of the population that fall victim to bureaucracy and the red tape of
large pharmaceutical companies.
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Appendices
Appendix A

Source: Cystic Fibrosis Foundation
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Appendix B

Source: Juvenile Diabetes Research Foundation
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Appendix C

Source: Michael J. Fox Foundation for Parkinson’s Research
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